title: Prophylaxis of nausea and vomiting after laparoscopic cholecystectomy with ramosetron: randomised controlled trial.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of ramosetron (a 5-hydroxytryptamine type 3 receptor antagonist) for the prevention of nausea and vomiting after laparoscopic cholecystectomy.
  
  
  METHODS
  Prospective, randomised, double-blind, placebo-controlled study.
  
  
  METHODS
  University and university-affiliated hospitals, Japan.
  
  
  METHODS
  100 patients, 65 women and 35 men, who had laparoscopic cholecystectomy.
  
  
  METHODS
  Patients were given either placebo or ramosetron at 3 different doses (0.15 mg, 0.3 mg, 0.6 mg) intravenously at the completion of operation. The general anaesthetic technique and postoperative analgesia were standard.
  
  
  METHODS
  Vomiting and safety were assessed for 0 to 24 hours and 24 to 48 hours after anaesthesia.
  
  
  RESULTS
  The number of patients who had a complete response (no nausea, no retching, no vomiting) during 0 to 24 hours after anaesthesia was 15/25 with placebo, 17/25 with ramosetron 0.15 mg, 23/25 with ramosetron 0.3 mg, and 23/25 with ramosetron 0.6 mg; The corresponding numbers from 24 to 48 hours were 16, 17, 23, and 23. No serious adverse events were observed in any of the groups.
  
  
  CONCLUSIONS
  Ramosetron 0.3 mg was the minimum effective dose for preventing postoperative nausea and vomiting during 0 to 48 hours after anaesthesia in patients undergoing laparoscopic cholecystectomy.
authors.affiliation: Department of Anaesthesiology, University of Tsukuba Institute of Clinical Medicine, Tsukuba City, Ibaraki, Japan. yfujii@md.tsukuba.ac.jp
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Fujii
authors.forename: Aki
authors.initials: A
authors.lastname: Uemura
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Tanaka
mesh_terms: D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D017081:Cholecystectomy, Laparoscopic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020250:Postoperative Nausea and Vomiting / Q000517:prevention & control*; D011446:Prospective Studies
chemical_list: D000932:Antiemetics; D001562:Benzimidazoles; C071315:ramosetron